

NYRx BLTG Program Update

What Pharmacy Providers and Prescribers Need to Know

Effective **March 20, 2024**, the following changes will be made to the Dispense Brand Name Drug When Less Expensive Than the Generic Program:

- **Nascobal®** and **Risperdal Consta®** will be **ADDED** to the program.
- **Nesina®**, **Rapamune® solution**, and **Vyvanse® chewable tablet** will be **REMOVED** from the program.

In conformance with State Education Law, a pharmacist shall dispense a less expensive, therapeutically equivalent drug containing the same active ingredients, dosage form, and strength as the drug prescribed/ordered. This includes substituting the brand name drug when NYRx has determined it to be the less expensive alternative for the patient. Brand name drugs included in this program:

- Do not require “Dispense as Written” (DAW) or “Brand Medically Necessary” on the prescription.
- Have a generic copayment.
- Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever is lower (SMAC/FUL are not applied).
- Do not require a new prescription if the drug is removed from this program.

Important Billing Information

Pursuant to this program, prescription claims submitted to the Medicaid program **do not require** the submission of a DAW Product Selection Code of “1”; Pharmacies should **submit DAW code 9** (Substitution Allowed by Prescriber but Plan Requests Brand). Pharmacies will receive an NCPDP reject response of “22” which means missing/invalid DAW code if other DAW codes are submitted. The only exception to this is DAW code “1” and “Brand Medically Necessary” on the prescription.

For a complete list, see [NYRx BLTG Program Brand Name Drugs](#) on the next page.

NYRx BLTG Drugs

NYRx BLTG Program Brand Name Drugs*		
Advair Diskus®	Epipen, JR	Renvela® tablet, powder pack
Advair HFA®	Forteo®	Risperdal Consta®
Alphagan P® 0.15%	Glumetza®	Restasis®
Alphagan P® 0.1%	Kazano®	Retin-A® cream
Amitiza®	Kitabis® Pak	Ritalin LA®
Apriso®	Kombiglyze® XR	Spiriva® HandiHaler®
Azopt™	Lialda®	Symbicort®
Bethkis®	Nascobal®	Tegretol® suspension
Cellcept® suspension	Nexavar®	Tegretol® XR
Combigan®	NuvaRing®	Trileptal® suspension
Copaxone® 20mg SQ	Onglyza®	Vascepa®
Daytrana®	Oseni®	Ventolin® HFA
Depakote® Sprinkle	Pentasa®	Votrient®
Dexilant®	Pradaxa®	Vyvanse® capsule
Dymista®	Protonix® suspension	Xopenex HFA®
Epipen	Pylera®	Zegerid® Rx

* This list is subject to change. For the most recent updates, see the [Brand Less than Generic Program Updates](#).

* Drugs in this program may be subject to prior authorization requirements of other pharmacy programs.

Resources

- [NYRx Brand Less Than Generic Program](#)
- [NYRx Education & Outreach Website](#)
- [NYRx Preferred Drug List](#)

Contact Information

The NYRx Education & Outreach Call Center is available by phone at 1-833-967-7310 from 8:00 AM to 5:00 PM ET, Monday through Friday, excluding holidays, or by email at NYRxEO@magellanhealth.com.

The NYRx Education & Outreach team hosts virtual office hours every week for stakeholders to ask questions related to NYRx and care coordination. Office hours are also available by appointment. For more information, email NYRxEO@magellanhealth.com or visit the [NYRx Education & Outreach website](#).